1. Preface

• 1.1 Report Description and Scope

• 1.2 Research Objectives

• 1.3 Key Questions Answered in This Report

• 1.4 Intended Audience

• 1.5 Currency and Pricing Conventions Used

2. Executive Summary

• 2.1 Global Pulmonary Embolism Market Snapshot

• 2.2 Key Findings and Highlights

• 2.3 Market Attractiveness Analysis by Segment

• 2.4 Epidemiological Overview of Pulmonary Embolism (PE) and Venous Thromboembolism (VTE)

• 2.5 Analyst Recommendations

3. Market Introduction

• 3.1 Definition and Scope of Pulmonary Embolism (PE) Market

• 3.2 Pathophysiology of PE: Blood Clot Formation, Embolus Migration, and Pulmonary Artery Obstruction

• 3.3 Classification of Pulmonary Embolism by Risk Stratification

• 3.3.1 Massive (High-Risk) PE — Hemodynamic Instability and High Mortality Risk

• 3.3.2 Submassive (Intermediate-Risk) PE — Right Ventricular Dysfunction Without Shock

• 3.3.3 Low-Risk PE — Preserved Hemodynamic Status

• 3.4 Relationship Between Deep Vein Thrombosis (DVT) and Pulmonary Embolism

• 3.5 Role of Pulmonary Embolism Response Teams (PERT) in Modern Clinical Practice

• 3.6 Regulatory Framework and Clinical Guidelines

• 3.6.1 U.S. FDA Approvals and CHEST Guidelines for PE Management

• 3.6.2 European Society of Cardiology (ESC) Guidelines for VTE/PE Diagnosis and Treatment

• 3.6.3 Asian Regulatory Standards and National Clinical Practice Guidelines (NMPA China, MHLW Japan)

• 3.7 Value Chain Analysis

• 3.7.1 Pharmaceutical API Manufacturing and Drug Formulation (Anticoagulants, Thrombolytics)

• 3.7.2 Medical Device Design, Engineering, and Manufacturing (Thrombectomy Systems, Vena Cava Filters)

• 3.7.3 Diagnostic Equipment and Point-of-Care Test Kit Manufacturing

• 3.7.4 Hospital and Specialty Clinic Procurement, Distribution, and Pharmacy Dispensing

• 3.7.5 Patient Monitoring, Homecare Management, and Remote Diagnostics

• 3.8 Industry Ecosystem Map

4. Research Methodology

• 4.1 Research Design and Framework

• 4.2 Primary and Secondary Data Sources

• 4.3 Data Triangulation and Epidemiological Modeling Approach

• 4.4 Market Size Estimation Methodology (Pharma Revenue, Device Sales, Diagnostic Volume)

• 4.5 Assumptions and Limitations

• 4.6 List of Abbreviations

5. Market Dynamics

• 5.1 Market Drivers

• 5.1.1 Rising Incidence of Venous Thromboembolism (VTE) and Blood Clots Due to Aging Population, Sedentary Lifestyles, and Obesity Epidemic

• 5.1.2 Growing Adoption of Direct Oral Anticoagulants (DOACs) — Apixaban, Rivaroxaban, Dabigatran, Edoxaban — as First-Line PE Treatment

• 5.1.3 Increasing Demand for Minimally Invasive Interventional Therapies (Catheter-Directed Thrombolysis, Mechanical Thrombectomy)

• 5.1.4 Rising Prevalence of PE Risk Comorbidities: Cancer, Cardiovascular Diseases, Surgical Procedures, Hormone Replacement Therapy, Oral Contraceptive Use

• 5.1.5 Advancements in Diagnostic Technologies: AI-Integrated CT Pulmonary Angiography (CTPA), Multi-Detector CT (MDCT), Dual-Energy CT (DECT)

• 5.1.6 Expanding Healthcare Infrastructure and Rising Reimbursement Policies in Emerging Markets

• 5.1.7 Integration of AI and Machine Learning in PE Risk Stratification and CTPA Image Interpretation

• 5.2 Market Restraints

• 5.2.1 Diagnostic Challenges: Non-Specific PE Symptoms Overlapping with Anxiety, Heart Failure, and Pneumonia Leading to Delayed Diagnosis

• 5.2.2 Bleeding Risk and Adverse Events Associated with Anticoagulant and Thrombolytic Therapies

• 5.2.3 High Cost of Interventional Devices (Mechanical Thrombectomy Systems) Limiting Adoption in Low- and Middle-Income Countries

• 5.2.4 Complexity of PE Management in Anticoagulant-Naïve, Cancer-Associated, and Pediatric Populations

• 5.3 Market Opportunities

• 5.3.1 Innovation in Next-Generation Anticoagulants: Factor XI and Factor XIIa Inhibitors for Improved Safety Profiles

• 5.3.2 Growing Adoption of Ultrasound-Assisted Catheter-Directed Thrombolysis (USCDT) and Advanced Aspiration Thrombectomy Systems

• 5.3.3 Expanding Application of Telemedicine, Remote Monitoring, and AI-Driven Clinical Decision Support for Outpatient PE Management

• 5.3.4 Rising Clinical Trials and Government Funding for Novel Antithrombotic Therapies and Genomic/Personalized Medicine Approaches

• 5.3.5 Growing Opportunity in Point-of-Care (POC) D-Dimer Testing for Rapid PE Rule-Out in Emergency and Remote Settings

• 5.4 Market Challenges

• 5.4.1 Limited Access to PERT (Pulmonary Embolism Response Team) Infrastructure in Non-Tertiary Hospitals and Developing Countries

• 5.4.2 Regulatory Hurdles for Combination Drug-Device PE Treatment Products

• 5.4.3 Lack of Long-Term Real-World Evidence for Novel Interventional Devices in Submassive PE

• 5.5 Porter's Five Forces Analysis

• 5.5.1 Threat of New Entrants

• 5.5.2 Bargaining Power of Suppliers (API Manufacturers, Medical Device Component Suppliers)

• 5.5.3 Bargaining Power of Buyers (Hospital Networks, Government Payers, Managed Care Organizations)

• 5.5.4 Threat of Substitute Treatments (Compression Stockings, Vena Cava Filters, Surgical Embolectomy)

• 5.5.5 Competitive Rivalry Among Existing Players

• 5.6 PESTLE Analysis

• 5.7 Pipeline Analysis: PE Drug and Device Clinical Trials in Phase I, II, and III

• 5.8 Epidemiology-Based Market Forecasting Framework

• 5.9 Reimbursement and Health Technology Assessment (HTA) Landscape

• 5.10 Impact of AI and Digital Health on PE Diagnosis and Treatment Pathways

6. Global Pulmonary Embolism Market Analysis, By Symptoms

• 6.1 Overview and Key Findings

• 6.2 Shortness of Breath (Dyspnea) (Dominant Segment — Highest Market Share in 2025)

• 6.2.1 Market Size and Forecast

• 6.2.2 Prevalence Across High-Risk Demographics (Aging Population, Obese, Post-Surgical, Cancer Patients)

• 6.3 Chest Pain

• 6.3.1 Market Size and Forecast

• 6.4 Cough (Including Hemoptysis — Blood-Tinged Sputum)

• 6.4.1 Market Size and Forecast

• 6.5 Irregular Heartbeat (Arrhythmia) (Fastest Growing Symptom Segment)

• 6.5.1 Market Size and Forecast

• 6.5.2 Rising Screening of Cardiac Rhythm Abnormalities — Increased Awareness of PE-Arrhythmia Association

• 6.6 Cyanosis (Bluish Skin Discoloration)

• 6.6.1 Market Size and Forecast

• 6.7 Dizziness and Syncope

• 6.7.1 Market Size and Forecast

• 6.8 Fever

• 6.8.1 Market Size and Forecast

• 6.9 Others (Leg Pain, Leg Swelling — DVT Complication, Anxiety, Rapid Pulse)

7. Global Pulmonary Embolism Market Analysis, By Diagnosis

• 7.1 Overview and Key Findings

• 7.2 CT Scan (CT Pulmonary Angiography — CTPA) (Dominant Segment — Gold Standard for PE Diagnosis)

• 7.2.1 Market Size and Forecast

• 7.2.2 Technology Innovations: Multi-Detector CT (MDCT), Dual-Energy CT (DECT), 3D Reconstruction Software

• 7.2.3 AI-Integrated CTPA Analysis for Early Subsegmental PE Detection

• 7.3 D-Dimer Test (Fastest Growing Diagnosis Segment)

• 7.3.1 Market Size and Forecast

• 7.3.2 Point-of-Care (POC) D-Dimer Testing: Rapid PE Rule-Out in Emergency and Outpatient Settings

• 7.3.3 Integration into Multi-Marker Diagnostic Panels for VTE, Cardiac Ailments, and Sepsis Assessment

• 7.4 Chest X-Ray

• 7.4.1 Market Size and Forecast

• 7.5 Echocardiography (ECG)

• 7.5.1 Market Size and Forecast

• 7.5.2 Bedside Echocardiography for Right Ventricular Dysfunction Detection in Submassive PE

• 7.6 MRI (Magnetic Resonance Pulmonary Angiography — MRPA)

• 7.6.1 Market Size and Forecast

• 7.7 Pulmonary Angiography (Gold Standard in Complex Cases)

• 7.7.1 Market Size and Forecast

• 7.8 Venous Ultrasound (Doppler Ultrasound for DVT Detection)

• 7.8.1 Market Size and Forecast

• 7.9 Venography

• 7.9.1 Market Size and Forecast

• 7.10 Others (V/Q Scintigraphy, Biomarkers — Troponin, BNP, NT-proBNP)

8. Global Pulmonary Embolism Market Analysis, By Treatment

• 8.1 Overview and Key Findings

• 8.2 Medications (Dominant Treatment Segment — Highest Market Share in 2025)

• 8.2.1 Market Size and Forecast

• 8.2.2 Anticoagulants — Direct Oral Anticoagulants (DOACs)

• 8.2.2.1 Apixaban (Eliquis — Bristol-Myers Squibb/Pfizer) — Market Leader

• 8.2.2.2 Rivaroxaban (Xarelto — Bayer/Janssen)

• 8.2.2.3 Dabigatran Etexilate (Pradaxa — Boehringer Ingelheim)

• 8.2.2.4 Edoxaban (Savaysa/Lixiana — Daiichi Sankyo)

• 8.2.3 Anticoagulants — Parenteral and Traditional

• 8.2.3.1 Unfractionated Heparin (UFH)

• 8.2.3.2 Low Molecular Weight Heparin (LMWH — Enoxaparin, Dalteparin, Tinzaparin)

• 8.2.3.3 Fondaparinux Sodium (Arixtra — Aspen Pharma)

• 8.2.3.4 Vitamin K Antagonists (Warfarin/Coumadin)

• 8.2.4 Thrombolytic Therapy (Systemic and Catheter-Directed)

• 8.2.4.1 Alteplase (Activase — Genentech/Roche)

• 8.2.4.2 Tenecteplase, Streptokinase, Urokinase

• 8.3 Mechanical Devices (Fastest Growing Treatment Segment)

• 8.3.1 Market Size and Forecast

• 8.3.2 Mechanical Thrombectomy Systems

• 8.3.2.1 Penumbra Lightning Flash 2.0 (Penumbra Inc. — Jan 2025 Launch of Element Vascular Access System)

• 8.3.2.2 Inari Medical FlowTriever System — Large-Bore Aspiration Thrombectomy

• 8.3.2.3 Inquis Medical Aventus Thrombectomy System (AVENTUS IDE Trial Enrollment Completed Jan 2025)

• 8.3.2.4 Argon Medical Devices Cleaner Pro Thrombectomy System (CLEAN-PE Multicenter Study, Jan 2025)

• 8.3.3 Ultrasound-Assisted Catheter-Directed Thrombolysis (USCDT) — EKOS System (Boston Scientific)

• 8.3.4 Inferior Vena Cava (IVC) Filters — Retrievable and Permanent

• 8.4 Surgery

• 8.4.1 Market Size and Forecast

• 8.4.2 Open Surgical Embolectomy (Cardiothoracic Surgery — High-Risk Massive PE)

• 8.4.3 Extracorporeal Membrane Oxygenation (ECMO) for Refractory Massive PE

• 8.5 Others (Supportive Care: Oxygen Therapy, Hemodynamic Support, Compression Stockings, Rehabilitation)

9. Global Pulmonary Embolism Market Analysis, By Distribution Channel

• 9.1 Overview and Key Findings

• 9.2 Hospital Pharmacy (Dominant Channel — Highest Revenue in 2025)

• 9.2.1 Market Size and Forecast

• 9.2.2 Role of Hospital Pharmacists in Anticoagulant Dosing, Monitoring, and Adverse Event Management

• 9.3 Retail Pharmacy

• 9.3.1 Market Size and Forecast

• 9.3.2 Outpatient DOAC Prescriptions for Long-Term PE Management (Post-Discharge)

• 9.4 Online Pharmacy (Fastest Growing Distribution Channel)

• 9.4.1 Market Size and Forecast

• 9.4.2 Telepharmacy, E-Prescribing, and Digital Health Application Integration

• 9.4.3 Competitive Pricing and Convenience Driving Patient Preference

• 9.5 Others (Government Institutional Procurement, Direct Supply to Specialty Clinics)

10. Global Pulmonary Embolism Market Analysis, By End User

• 10.1 Overview and Key Findings

• 10.2 Hospitals (Dominant Segment — Largest Revenue in 2025)

• 10.2.1 Market Size and Forecast

• 10.2.2 Multidisciplinary PERT Teams (Pulmonologists, Radiologists, Cardiologists, Emergency Medicine Specialists) for Complex PE Management

• 10.2.3 High-Volume Diagnostic and Interventional Infrastructure (CT, Cath Lab, ICU)

• 10.3 Specialty Clinics (Hematology, Cardiology, Vascular Surgery, Pulmonology Clinics)

• 10.3.1 Market Size and Forecast

• 10.3.2 Anticoagulation Management Clinics and Follow-Up Care for Chronic VTE

• 10.4 Homecare (Fastest Growing End-User Segment)

• 10.4.1 Market Size and Forecast

• 10.4.2 Shift to Outpatient and Home-Based PE Management via DOAC Therapy and Remote Monitoring

• 10.4.3 Telemedicine Platforms and Wearable Monitoring Devices for Home-Based PE Care

• 10.5 Others (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Emergency Departments)

11. Global Pulmonary Embolism Market Analysis, By Region

• 11.1 Overview and Regional Key Findings

• 11.2 North America (Dominant Region — Largest Market Share in 2025)

• 11.2.1 Market Size and Forecast

• 11.2.2 United States

• 11.2.2.1 Market Size and Forecast

• 11.2.2.2 High PE Incidence Driven by Obesity Epidemic, Aging Baby Boomer Population, Cancer Prevalence

• 11.2.2.3 FDA Pipeline: Novel Factor XI/XIIa Inhibitors and Next-Generation Thrombectomy IDE Trials

• 11.2.2.4 Strong PERT Program Adoption in Major Academic Medical Centers

• 11.2.3 Canada

• 11.2.3.1 Market Size and Forecast

• 11.2.3.2 Universal Healthcare Coverage and Reimbursement for DOACs

• 11.3 Europe

• 11.3.1 Market Size and Forecast

• 11.3.2 Germany

• 11.3.3 United Kingdom — NICE Guidelines and NHS Formulary Coverage for Rivaroxaban and Apixaban

• 11.3.4 France

• 11.3.5 Italy

• 11.3.6 Spain

• 11.3.7 Rest of Europe

• 11.4 Asia Pacific (Fastest Growing Region)

• 11.4.1 Market Size and Forecast

• 11.4.2 China

• 11.4.2.1 Market Size and Forecast

• 11.4.2.2 Rising PE Burden in Aging Chinese Population; Expanding Hospital Infrastructure

• 11.4.3 India

• 11.4.3.1 Market Size and Forecast

• 11.4.3.2 Expanding Pharmaceutical and Diagnostic Sectors; Growing Awareness of VTE

• 11.4.4 Japan — MHLW-Approved DOACs and High-Technology Diagnostic Adoption

• 11.4.5 South Korea — Advanced Healthcare System and Medical Device Innovation

• 11.4.6 Australia and New Zealand

• 11.4.7 ASEAN (Vietnam, Indonesia, Thailand, Malaysia, Philippines)

• 11.4.8 Rest of Asia Pacific

• 11.5 Latin America

• 11.5.1 Market Size and Forecast

• 11.5.2 Brazil — Growing Hospital Infrastructure and Generic DOAC Market

• 11.5.3 Mexico — Increasing Healthcare Expenditure and VTE Awareness Programs

• 11.5.4 Rest of Latin America

• 11.6 Middle East & Africa

• 11.6.1 Market Size and Forecast

• 11.6.2 GCC Countries (Saudi Arabia, UAE, Qatar) — Vision 2030-Driven Healthcare Infrastructure Development

• 11.6.3 South Africa

• 11.6.4 Rest of Middle East & Africa

12. Competitive Landscape

• 12.1 Global Market Share Analysis by Key Players

• 12.2 Competitive Benchmarking Matrix (Pharmaceutical and Medical Device Players)

• 12.3 Vendor Positioning Grid (Market Leaders, Challengers, Niche Interventional Device Players, Emerging Biotech)

• 12.4 Key Strategic Developments

• 12.4.1 New Product Launches (Penumbra Element Vascular Access System for VTE, Jan 2025; Flow Medical $5M Seed Funding for PE Device, Dec 2024)

• 12.4.2 Clinical Trials and Pipeline Updates (Inquis Medical AVENTUS IDE Trial; Argon Medical CLEAN-PE Study; Factor XI Inhibitor Phase III Programs)

• 12.4.3 Mergers, Acquisitions, and Strategic Alliances (Bristol-Myers Squibb/Pfizer Eliquis Alliance; Daiichi Sankyo-AstraZeneca Collaboration)

• 12.4.4 Regulatory Approvals and Label Expansions

• 12.4.5 Geographic Expansion and Market Access Strategies in Asia Pacific and Emerging Markets

• 12.5 Patent Landscape and IP Pipeline Analysis

• 12.6 Market Concentration Analysis

13. Company Profiles

The final report includes a complete list of companies.

• 13.1 Bristol-Myers Squibb Company

  • 13.1.1 Company Overview

  • 13.1.2 Financial Performance

  • 13.1.3 Product Portfolio

  • 13.1.4 Strategic Initiatives

  • 13.1.5 SWOT Analysis

• 13.2 Pfizer Inc.

• 13.3 Bayer AG

• 13.4 Boehringer Ingelheim International GmbH

• 13.5 Johnson & Johnson (Janssen Pharmaceuticals)

• 13.6 Daiichi Sankyo Company, Limited

• 13.7 Sanofi S.A.

• 13.8 F. Hoffmann-La Roche Ltd. (Genentech)

• 13.9 AstraZeneca plc

• 13.10 Inari Medical, Inc.

• 13.11 Penumbra, Inc.

• 13.12 Boston Scientific Corporation

• 13.13 Abbott Laboratories

• 13.14 Baxter International Inc.

• 13.15 Fresenius Kabi AG

14. Recent Developments and Industry News

• 14.1 Key Product Launches and FDA/EMA Approvals (2024–2026)

• 14.2 Clinical Trial Updates and Pipeline Milestones

• 14.3 Mergers, Acquisitions, Partnerships, and Funding Rounds

• 14.4 Regulatory and Clinical Guideline Updates (ESC, CHEST, NICE, FDA)

15. Appendix

• 15.1 Detailed Research Methodology

• 15.2 Epidemiological Data Sources and VTE Incidence Tables

• 15.3 List of Tables and Figures

• 15.4 List of Abbreviations

• 15.5 Data Sources and References

• 15.6 About the Publisher

16. Disclaimer